The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug alert for the Abrysvo (made by Pfizer) and ...

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in ...

The UK's medicines regulator has warned NHS healthcare staff about an increased risk of a condition affecting the nerves in ...

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

Arexvy dominates U.S. retail vaccine market in Q3; management optimistic but mindful of competitive landscape. Investment recommendation: "Speculative Buy" on GSK, ...

Arexvy is just the first downstream result of this discovery to be approved by the FDA, and more will likely follow soon. Pfizer’s RSV vaccine for adults will probably be approved later this ...

GSK plc today announced that AREXVY is now available in the US at all major retail pharmacies. In June, the Advisory Committee on Immunization Practices recommended that persons 60 years of age ...

Arexvy was also evaluated in a phase 2b trial (ClinicalTrials.gov Identifier: NCT05921903) that included individuals aged 18 years and older who received lung or renal transplant and were at ...

Well in advance of the fall and winter RSV season, GSK's vaccine Arexvy is now available in major U.S. retail pharmacies, the company said.

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified. See what to expect from GSK's Q3.